
Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.
Come Rain or Shine
over 14 years ago
HBA Woman of the Year 2012over 14 years ago
Scotland, Independence, and Pharmaover 14 years ago
Emerging Markets: Setting a New Agendaover 14 years ago
Shortages and Sunshineover 14 years ago
Pharm Exec Ad Stars 2012over 14 years ago
Providing Access Nowover 14 years ago
Navigating M&A Complexitiesover 14 years ago
Country Report: Ukraineover 14 years ago
Think Digital First




